SynthesisRheumatology (Oxford, England)2026
Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis.
Synthesis in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics and prognostic markers of anti-MDA5 antibody-positive dermatomyositis-associated interstitial lung disease: a retrospective cohort study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAnti-MDA5 antibody-positive DM (MDA5+DM) is frequently complicated by rapidly progressive interstitial lung disease (RP-ILD). The current study aims to identify predictors for the development of RP-ILD in MDA5+DM, thereby providing an objective basis for early intervention strategies.
methodsWe searched the PubMed, Embase, Web of Science and Cochrane Library databases and extracted studies published before December 2024. Two reviewers extracted data and assessed risk of bias. Population characteristics, clinical features and laboratory indicators were systematically summarized. For the overall main effects, results were presented as standardized mean differences (SMDs), odds ratios (ORs) and corresponding 95% CIs.
resultsTwenty-seven cohorts with 2579 patients were included in this meta-analysis. The results demonstrated that clinical characteristics predictive of RP-ILD risk factors included advanced age, male sex, fever, skin ulcers and arthritis. Specifically, the RP-ILD group exhibited significantly elevated levels of laboratory parameters including CRP, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), ferritin, ESR, leukocytes, Krebs von den Lungen-6 (KL-6), alanine aminotransferase (ALT), cartilage glycoprotein 39, positive anti-Ro52 antibodies and high-titre anti-MDA5 antibodies. Conversely, the RP-ILD group demonstrated significantly reduced levels of lymphocytes, albumin, PaO2/FiO2 ratio and CD3+CD4+ T cell count.
conclusionThis meta-analysis identified multiple clinical and laboratory parameters as significant predictors of RP-ILD progression in MDA5+DM patients. High-quality prospective studies are essential to validate these associations and identify additional biomarkers for the early prediction of RP-ILD onset in MDA5+DM patients, which will facilitate timely therapeutic interventions aimed at reducing mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.